Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) has reported strong growth for the second quarter (Q2) and first half (H1) of the fiscal year 2024-2025. The company’s consolidated revenue for Q2 rose by 17% year-on-year (YoY) to ₹2,242 crore, supported by significant demand in its contract development and manufacturing organization (CDMO) business. Piramal also […]
Piramal Pharma Solutions has announced an unprecedented $80 million expansion of its sterile injectables facility in Lexington, Kentucky. The company’s aggressive move aims to address the surging global demand for sterile injectable treatments. With this new investment, Piramal Pharma Solutions, part of the Piramal Pharma Limited group, is poised to become a leading force in […]
Piramal Pharma Solutions (PPS), a prominent Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (PPL) has opened its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK. This expansion marks a significant step in addressing the growing global demand for ADC manufacturing. Dignitaries Attend Ribbon-Cutting Ceremony The ribbon-cutting ceremony, formally […]